Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

Abstract Objective To evaluate trials of drugs that target amyloid to determine whether reductions in amyloid levels are likely to improve cognition. Design Instrumental variable meta-analysis. Setting 14 randomized controlled trials of drugs for the prevention or treatment of Alzheimer’s disease that targeted an amyloid mechanism, identified from ClinicalTrials.gov. Population Adults enrolled in randomized controlled trials of amyloid targeting drugs. Inclusion criteria for trials vary, but typically include adults aged 50 years or older with a diagnosis of mild cognitive impairment or Alzheimer’s disease, and amyloid positivity at baseline. Main outcome measures Analyses included trials for which information could be obtained on both change in brain amyloid levels measured with amyloid positron emission tomography and change in at least one cognitive test score reported for each randomization arm. Results Pooled results from the 14 randomized controlled trials were more precise than estimates from any single trial. The pooled estimate for the effect of reducing amyloid levels by 0.1 standardized uptake value ratio units was an improvement in the mini-mental state examination score of 0.03 (95% confidence interval −0.06 to 0.1) points. This study provides a web application that allows for the re-estimation of the results when new data become available and illustrates the magnitude of the new evidence that would be necessary to achieve a pooled estimate supporting the benefit of reducing amyloid levels. Conclusions Pooled evidence from available trials reporting both reduction in amyloid levels and change in cognition suggests that amyloid reduction strategies do not substantially improve cognition.

[1]  Olivier Salvado,et al.  Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL , 2018, NeuroImage.

[2]  J. Clarke,et al.  Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. , 2018, Journal of Alzheimer's disease : JAD.

[3]  J. Cummings,et al.  Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future , 2018, Journal of Alzheimer's disease : JAD.

[4]  Ahmed Elmaraezy,et al.  Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials , 2017, BMC Neurology.

[5]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[6]  L. Lannfelt,et al.  Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody , 2016, Alzheimer's Research & Therapy.

[7]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[8]  Donald A. Berry,et al.  Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease , 2016, Alzheimer's & dementia.

[9]  R. Doody,et al.  How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond? , 2015, The Clinical neuropsychologist.

[10]  M. Baiocchi,et al.  Instrumental variable methods for causal inference , 2014, Statistics in medicine.

[11]  L. Lannfelt,et al.  Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[12]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[13]  K. Mullane,et al.  Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.

[14]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[15]  F. Panza,et al.  Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease , 2012, Expert review of clinical immunology.

[16]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[17]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[18]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[19]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[20]  Nick C Fox,et al.  A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease , 2009, Neurology.

[21]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[22]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[23]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[24]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. , 2006, Journal of Alzheimer's disease : JAD.